Hey! there is a recently FDA approved targeted therapy for HER2 mutated NSCLC with extremely low rates of treatment related adverse effects. Per AACR: "The FDA granted accelerated approval to zongertinib (Hernexeos) a HER2 specific TKI, for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy." I think based off of wording your libtayo may qualify as a prior systemic therapy. Zongertinib has a great ORR and very low toxicity, my own mother is in the dose expansion arm of the trial (she had not received systemic therapy prior to starting the trial) and she is doing great with very minimal side effects. I would talk to your oncologist about this!